Disease · MONDO_0005028

esophageal adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. esophageal adenocarcinoma. Diseases, record MONDO_0005028. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005028

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: esophageal adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005028; Open Targets
Other names: EAC, adenocarcinoma - esophagus, adenocarcinoma - oesophagus, adenocarcinoma of esophagus, adenocarcinoma of oesophagus, adenocarcinoma of the esophagus, adenocarcinoma of the oesophagus, esophagus adenocarcinoma, oesophageal adenocarcinoma, oesophagus adenocarcinoma; Open Targets
Disease Ontology: DOID:4914; Disease Ontology
NCI Thesaurus: C4025; NCI Thesaurus
Orphanet: ORPHA:99976; Orphanet
Highest stage of its drugs: Phase 3, for 20 of its 105 drugs, from ClinicalTrials.gov; Open Targets

Drugs105

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	52	52	48	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	48	48	45	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	38	38	38	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	26	26	26	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	18	18	17	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets

1 to 10 of 105

See all 105 drugs

Targets134

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	9	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	9	Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 3	https://conductscience.org/library/genes/2064	Drugs and targets
PDCD1	Programmed cell death protein 1	7	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/3791	Drugs and targets
TUBA1A	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	5	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 134

See all 134 targets

Trials146

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02564263	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)	Phase 3	628	2019-11-20	Esophageal Carcinoma, Esophagogastric Junction Carcinoma	DOCETAXEL, IRINOTECAN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00680901	LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib	Phase 3	545	2013-10-29	Neoplasms, Gastrointestinal Tract	CAPECITABINE, LAPATINIB, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00381706	Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer	Phase 2	245	2017-03-15	Esophageal Cancer	CETUXIMAB, CISPLATIN, EPIRUBICIN, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01196390	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Phase 3	203	2021-05-04	Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7	TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01246960	A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer	Phase 2	168	2014-10-08	Stomach Cancer, Esophageal Cancer	FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT03933449	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study	Phase 3	123	2020-02-26	Esophageal Carcinoma, Esophagogastric Junction Carcinoma	DOCETAXEL, IRINOTECAN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02559687	Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)	Phase 2	121	2019-07-17	Esophageal Carcinoma, Esophagogastric Junction Carcinoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00086996	S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction	Phase 2	98	2012-04-03	Esophageal Cancer	FLUOROURACIL, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00033657	Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer	Phase 2	97	2011-07-19	Esophageal Cancer, Gastric Cancer	CISPLATIN, IRINOTECAN HYDROCHLORIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03365791	PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies	Phase 2	76	2021-04-19	Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma	IERAMILIMAB, SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 146

See all 146 trials

Comparisons in its trials24

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE)	301 of 314	288 of 296	610	NCT02564263	Trial comparisons
Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)	40 of 314	42 of 296	610	NCT02564263	Trial comparisons
CapeOx Plus Lapatinib vs CapeOx Plus Placebo: Percentage of Participants With Clinical Benefit (CB)	199 of 249	188 of 238	487	NCT00680901	Trial comparisons
CapeOx Plus Lapatinib vs CapeOx Plus Placebo: Percentage of Participants With a Confirmed Complete Response (CR) or a Partial Response (PR)	131 of 249	94 of 238	487	NCT00680901	Trial comparisons
Chemoradiation and Trastuzumab (Arm 1) vs Chemoradiation (Arm 2): Number of Participants With Any Cardiac Adverse Events Regardless of Attribution	30 of 95	24 of 96	191	NCT01196390	Trial comparisons
Chemoradiation and Trastuzumab vs Chemoradiation: deaths from any cause	53 of 95	55 of 96	191	NCT01196390	Trial comparisons
Chemoradiation and Trastuzumab vs Chemoradiation: serious adverse events	51 of 95	34 of 96	191	NCT01196390	Trial comparisons
Ramucirumab and mFOLFOX6 vs Placebo and mFOLFOX6: serious adverse events	48 of 82	32 of 80	162	NCT01246960	Trial comparisons
Ramucirumab and mFOLFOX6 vs Placebo and mFOLFOX6: Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies	0 of 81	1 of 77	158	NCT01246960	Trial comparisons
PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause	9 of 76	18 of 76	152	NCT03365791	Trial comparisons

1 to 10 of 24

See all 24 comparisons in its trials

Papers from its trials51

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34973513	RESULT	1	PubMed
33026938	RESULT	1	PubMed
31809243	RESULT	1	PubMed
27911128	RESULT	1	PubMed
21258083	RESULT	1	PubMed
21217058	RESULT	1	PubMed
20354452	RESULT	1	PubMed
18845990	RESULT	1	PubMed
16303863	RESULT	1	PubMed
15542799	RESULT	1	PubMed

1 to 10 of 51

See all 51 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005028

GET https://conductscience.org/api/diseases/v1/MONDO_0005028/drugs?page=2

API reference For AI assistants